Spark Therapeutics Announces Pricing of Its Initial Public Offering

PHILADELPHIA, Jan. 30, 2015  -- Spark Therapeutics announced today the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Spark. In addition, Spark has granted the underwriters an option to purchase up to 1,050,000 additional shares of common stock at the public offering price, less the underwriting discount. Spark's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the symbol "ONCE" on January 30, 2015.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as lead book-running managers for the offering. Cowen and Company, LLC is acting as lead manager and Sanford C. Bernstein & Co., LLC is acting as co-manager.

This offering is being made only by means of a prospectus. A copy of the prospectus may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, or by telephone at +1 (800) 221-1037, or by email at This email address is being protected from spambots. You need JavaScript enabled to view it..

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Spark Therapeutics     

Spark is a late clinical-stage gene therapy company seeking to develop one-time, life-altering treatments for debilitating genetic diseases, with an initial focus on treating rare diseases. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases.